OCN Exam Guide 2026: FREE ONCC Oncology Nurse Playbook

OCN Exam Guide 2026: The Blueprint-First, Immunotherapy-Era Playbook

The Oncology Certified Nurse (OCN) credential is the definitive entry-level oncology nursing certification in North America. Administered by the Oncology Nursing Certification Corporation (ONCC) and aligned with the Oncology Nursing Society (ONS) Scope and Standards of Practice, the OCN validates that an RN can safely manage the full adult cancer care continuum — from screening and risk assessment, through chemotherapy, radiation, immunotherapy, and stem cell transplant, into survivorship and end-of-life care.

If you have a current unencumbered RN license, two years of RN practice, 2,000 hours of adult oncology practice in the last four years, and 10 contact hours of oncology CE in the last three, the OCN turns that experience into a portable, recruiter-recognized credential that unlocks clinical-ladder pay, infusion-room charge roles, nurse navigator positions, and a clear pathway to advanced ONCC credentials (BMTCN, CBCN, AOCNP).

This 2026 guide is the most current, blueprint-accurate OCN resource on the internet. It uses the verified ONCC fees for 2026, the brand-new 2026 Test Content Outline (published by ONCC in November 2025 and effective for all 2026 testing), the most recent published ONCC pass rates (2023 and 2024), and it covers the two content areas every other guide under-serves: immune-related adverse events (irAEs) from checkpoint inhibitors and CAR-T cell therapy toxicities (CRS, ICANS) — both now explicitly listed under Oncologic Emergencies in the 2026 TCO. It also walks USP 800 hazardous-drug compliance — a major 2026 inspection focus.

Key 2026 blueprint changes you must know: Symptom Management (renamed "Symptom Management and Supportive Care") grew from 21% to 25%, Oncologic Emergencies jumped from 12% to 16% (and now explicitly names CRS and ICANS as testable content), Treatment Modalities rose from 19% to 20%, while Care Continuum dropped from 19% to 14%, Oncology Nursing Practice fell from 17% to 15%, and Psychosocial Dimensions of Care from 12% to 10%. If you studied from pre-November 2025 materials, you are studying yesterday's exam — this guide is updated throughout.

OCN At-a-Glance (2026)

Primary sources: ONCC OCN page, 2026 OCN Test Content Outline (PDF) — effective 2026, ONCC Test Scores and Passing Score, ONCC Renewal Fees, 2024 Examination Statistics (PDF).

---

Start Your FREE OCN Prep Today

Start FREE OCN Practice QuestionsPractice questions with detailed explanations

Our question bank mirrors the official 2026 OCN Test Content Outline (effective 2026, published November 2025): Care Continuum (14%), Oncology Nursing Practice (15%), Treatment Modalities (20%), Symptom Management and Supportive Care (25%), Oncologic Emergencies (16%), and Psychosocial Dimensions of Care (10%). Every item has a full rationale. 100% free, no login required.

---

What the OCN Is (and Why It Is the Definitive Oncology Nursing Credential)

The OCN is a psychometrically validated, entry-level specialty certification for registered nurses caring for adult oncology patients. It is built on a Role Delineation Study (RDS) / Job Task Analysis (JTA) that ONCC repeats at least every five years, and it is governed by the ONCC Board of Directors in collaboration with ONS subject-matter experts. The current active Test Content Outline is the 2025 OCN Test Content Outline, which remains in effect for the 2026 testing year until ONCC publishes a new TCO based on the next RDS.

There are three reasons OCN dominates adult oncology nursing credentialing:

1. Alignment with the ONS Scope and Standards. Every domain on the blueprint maps directly to the ONS Oncology Nursing Scope and Standards of Practice — the same document accrediting bodies like The Joint Commission, QOPI (ONS Quality Oncology Practice Initiative), and Magnet use when surveying cancer programs. Employers do not need to educate themselves on what OCN means; it is the reference standard.
2. The credential ladder. OCN is the gateway to every other ONCC credential: BMTCN (Blood and Marrow Transplant), CBCN (Breast Care), CPHON/CPON (Pediatric Hematology Oncology), and the advanced-practice AOCNP (for NPs) and AOCNS (clinical nurse specialists). If you want any of those eventually, the OCN prep is the foundation.
3. Portability. More than 40,000 active OCNs practice across the United States and Canada. Because eligibility is defined by hours rather than program completion, the credential travels with you through job changes, state moves, and shifts from inpatient to ambulatory infusion or clinical-trials roles.

Who Should Take the OCN

The OCN is explicitly scoped to the RN with two years of RN experience and 2,000 oncology hours in the past four years. It is the right credential if you are:

• A staff RN on an inpatient medical oncology, hematology-oncology, or BMT floor
• An ambulatory infusion RN administering chemotherapy, immunotherapy, or biotherapy
• A clinical trials / research RN coordinating oncology protocols
• A radiation oncology RN supporting external beam, brachytherapy, or systemic radiopharmaceutical patients
• A nurse navigator, survivorship coordinator, or palliative-care RN whose caseload is primarily adult cancer patients
• An APP new to oncology (NP or CNS) who wants the entry-level credential before pursuing AOCNP/AOCNS
• A travel RN building a competitive oncology profile — most major cancer centers prefer or require OCN for agency placements in infusion roles

The OCN is not intended for new graduates, for RNs whose only cancer exposure is occasional floor patients, or for pediatric-exclusive nurses (pediatric oncology nurses should pursue CPHON instead).

Eligibility and Application Process

Initial eligibility (2026)

To sit for the OCN you must meet all four of the following:

1. Hold a current, active, unencumbered license as a registered nurse in the United States, its territories, or Canada at the time of application and testing.
2. Have a minimum of 2,000 hours of adult oncology nursing practice within the four years (48 months) prior to application. Practice may be clinical, administrative, educational, research, or consultative.
3. Have a minimum of two years (24 months) of experience as an RN within the four years prior to application.
4. Have completed 10 contact hours of nursing continuing education in oncology or an academic elective in oncology nursing within the three years (36 months) prior to application.

What counts as oncology practice

ONCC defines oncology practice broadly. These all count toward the 2,000-hour requirement:

• Direct care of adult cancer patients (inpatient, outpatient, infusion, radiation, BMT, palliative, hospice)
• Oncology-specific case management and navigation
• Oncology research coordination and clinical trials
• Oncology staff development, in-service education, or academic teaching
• Oncology nursing administration (manager, director, CNO of a cancer service line)
• Oncology-focused informatics and quality roles

Application steps

1. Create an ONCC account at oncc.org and complete the online application. You will enter license details, hours, and CE.
2. Attestation, not documentation. ONCC uses an attestation model for most applicants; you only submit documentation if selected for random audit. Keep your CE certificates and hour logs for 12 months.
3. Pay the fee ($300 ONS/APHON member, $420 non-member for 2026).
4. Authorization to Test (ATT) arrives by email from PSI within a few business days. The ATT opens a 90-day testing window.
5. Schedule with PSI — either at a PSI test center or via PSI online remote proctoring. Remote candidates must meet the system/environment requirements (single camera, no dual monitors, clear desk, private room).
6. Test day: bring two forms of government ID (primary must be photo), arrive 30 minutes early for a center test, or complete the OnVUE-style check-in for remote. You get 15 minutes for a tutorial + 3 hours for the 165 items. Results display the moment you click End.

Tip: ONS membership pays for itself. Membership is roughly $125/year, the OCN fee discount alone is $120, and members receive discounted access to the ONS/ONCC Chemotherapy Immunotherapy Certificate course, free CE, and the Clinical Journal of Oncology Nursing. If you are going to take OCN, join ONS before you apply.

Official 2026 Test Content Outline (Brand New — Published November 2025)

The OCN is built on six content domains. The 2026 OCN Test Content Outline — released by ONCC in November 2025 and active for the entire 2026 testing year — weights them as follows, drawn verbatim from the ONCC document:

Three takeaways for your study plan:

1. Symptom Management and Oncologic Emergencies now make up 41% of the exam (was 33% in 2025). Master these two domains first.
2. Oncologic Emergencies explicitly names "Immune-related adverse events (e.g., cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS))" as a testable subtopic — this is new in the 2026 TCO. See our deep-dive section below.
3. Targeted therapies now explicitly list "Immune cell, bispecific antibodies" — meaning bispecific T-cell engagers (teclistamab, talquetamab, elranatamab, mosunetuzumab, glofitamab, epcoritamab) are fair game.

Note: Some third-party sites still republish the older 2025 or 2022 weights. Always verify against the current ONCC 2026 TCO.

The sub-sections below give the high-yield content within each domain, mapped to how ONCC writes items.

Domain I — Care Continuum (14%)

High-yield subtopics (memorize these buckets):

• Health promotion and disease prevention — high-risk behaviors (tobacco, alcohol, UV exposure, HPV, H. pylori, Hep B/C, occupational exposures like asbestos and benzene); preventive practices (HPV vaccine, hepatitis B vaccine, sun protection)
• Screening and early detection — USPSTF guidelines for breast (mammography), cervical (Pap/HPV co-testing), colorectal (colonoscopy, FIT, Cologuard), lung (low-dose CT for 50-80 y/o with 20-pack-year history who currently smoke or quit within 15 years), prostate (PSA shared decision-making 55-69)
• Navigation and coordination of care — the RN navigator role, interdisciplinary tumor boards, oral-chemo adherence monitoring
• Advance care planning — advance directives, healthcare proxies, POLST/MOLST, goals-of-care conversations
• Epidemiology — modifiable vs. non-modifiable risk factors; genetic risk syndromes the OCN loves to test: BRCA1/BRCA2 (breast, ovarian, pancreatic, prostate), Lynch syndrome (colorectal, endometrial, gastric, ovarian), Li-Fraumeni (TP53, sarcomas, breast, brain, adrenocortical), FAP (APC gene, colorectal), MEN1/MEN2, Cowden (PTEN), Peutz-Jeghers
• Survivorship — rehabilitation, recurrence anxiety, sexuality and fertility, work reentry, lymphedema surveillance, cardio-oncology follow-up
• Treatment-related considerations — delayed-onset toxicities (cardiomyopathy from anthracyclines, pulmonary fibrosis from bleomycin, cognitive dysfunction, secondary malignancies like t-AML/t-MDS)
• End-of-life care — grief vs. anticipatory grief vs. complicated grief; hospice eligibility (prognosis ≤ 6 months); pharmacologic comfort (opioids, scopolamine for secretions, haloperidol for terminal agitation); non-pharmacologic measures (positioning, mouth care, family presence)

Domain II — Oncology Nursing Practice (15%)

• Scientific basis — carcinogenesis (initiation, promotion, progression), hallmarks of cancer (sustained proliferative signaling, evasion of apoptosis, angiogenesis, invasion/metastasis, immune evasion), immunology fundamentals (innate vs. adaptive, T-cell receptors, PD-1/PD-L1, CTLA-4), clinical-trial phases (I-IV) and informed consent, molecular/genetic testing (next-gen sequencing, HER2, EGFR, ALK, BRAF, KRAS, PD-L1 tumor proportion score, MSI-H, TMB)
• Site-specific cancer considerations — pathophysiology, common metastatic patterns (breast → bone/lung/liver/brain; lung → brain/bone/adrenal/liver; prostate → bone; colorectal → liver/lung; pancreatic → liver/peritoneum), diagnostic workup, prognosis, classification, TNM staging (Tumor size, Node involvement, Metastasis) and histologic grading (G1 well-differentiated to G4 undifferentiated)
• Scope and Standards of Practice — ONS accreditation bodies (Joint Commission, QOPI, Magnet/Pathway), collaboration, culturally congruent care, environmental health (USP 800 hazardous drug handling — covered in depth below), ethics and patient advocacy, EBP and research, leadership, legal and documentation, quality, resource utilization, self-care for compassion fatigue, nursing process standards
• Lab interpretation — CBC with differential (ANC calculation: ANC = WBC × (%segs + %bands) — neutropenic at < 1,500; severe at < 500), chemistries (LFTs, renal function, electrolytes), coagulation (PT/INR, PTT, fibrinogen, D-dimer), tumor markers (CEA for colorectal, CA 125 for ovarian, CA 19-9 for pancreatic, PSA for prostate, AFP + β-hCG for testicular/hepatocellular, CA 15-3 for breast)

Domain III — Treatment Modalities (20%)

This is where the exam goes deep on mechanism of action and safe administration. Memorize these classes:

Chemotherapy classes and MOA

Targeted therapies — Monoclonal antibodies (trastuzumab for HER2+; rituximab for CD20+; cetuximab for EGFR; bevacizumab for VEGF — bleeding, GI perforation, impaired wound healing, hypertension). Small-molecule kinase inhibitors (imatinib, erlotinib, osimertinib — oral, adherence-critical). Trastuzumab cardiotoxicity is typically reversible (contrast with doxorubicin).

Immunotherapy — Checkpoint inhibitors (pembrolizumab, nivolumab targeting PD-1; atezolizumab, durvalumab targeting PD-L1; ipilimumab targeting CTLA-4; cemiplimab, dostarlimab, tislelizumab). CAR-T cell therapy (tisagenlecleucel, axicabtagene, brexucabtagene, lisocabtagene, idecabtagene, ciltacabtagene). Bispecific T-cell engagers (BsAbs) — new 2026 TCO subtopic: blinatumomab (CD19×CD3, B-ALL), teclistamab and elranatamab (BCMA×CD3, multiple myeloma), talquetamab (GPRC5D×CD3, MM), mosunetuzumab and epcoritamab and glofitamab (CD20×CD3, B-NHL), tarlatamab (DLL3×CD3, small cell lung cancer). BsAbs require step-up dosing with CRS/ICANS REMS monitoring similar to CAR-T but typically milder grade. All three classes have unique toxicities covered in detail below.

Radiation — External beam (photons, IMRT, SBRT, protons); brachytherapy (LDR, HDR, permanent seed — radiation-safety principles: time, distance, shielding); systemic radiopharmaceuticals (I-131 for thyroid, Ra-223 for bone-metastatic prostate, Lu-177-PSMA, Y-90 radioembolization).

Surgery — curative, palliative, diagnostic (biopsy), reconstructive, prophylactic (bilateral mastectomy for BRCA+, prophylactic salpingo-oophorectomy).

HSCT — Autologous (self, used for myeloma and some lymphomas, no GVHD risk); Allogeneic (donor, used for AML/ALL/MDS, GVHD risk requires immunosuppression and GVHD surveillance — skin, liver, gut). Conditioning regimens (myeloablative vs. reduced-intensity). Post-transplant complications: engraftment syndrome, VOD/SOS (veno-occlusive disease), CMV reactivation, acute and chronic GVHD.

Vascular access devices (VADs) — peripheral IVs (short-term vesicant-free only), midlines (non-vesicants ≤ 4 weeks), PICCs, non-tunneled CVCs, tunneled catheters (Hickman, Broviac), implanted ports. Vesicant chemo requires a central line or carefully monitored peripheral access with blood return q 2-5 mL push. Extravasation protocols are VAD-specific.

Domain IV — Symptom Management and Supportive Care (25%)

The largest domain (up from 21% in 2025 — and renamed from "…and Palliative Care" to "…and Supportive Care" in the 2026 TCO). Expect situational vignettes on VADs, pain, CINV, mucositis, fatigue, nutrition/cachexia, and alterations across hematologic, immunological, GI, GU, integumentary, respiratory, cardiovascular, neurological, and musculoskeletal systems:

• Pain management — WHO analgesic ladder, opioid rotation (morphine → hydromorphone → fentanyl equivalence tables), opioid-induced constipation (prescribe a stimulant laxative prophylactically — senna ± docusate; use naloxegol/methylnaltrexone for refractory OIC), breakthrough dosing (10-20% of 24-hour total, q1h PRN), neuropathic adjuvants (gabapentin, pregabalin, duloxetine), interventional options (celiac plexus block for pancreatic cancer)
• CINV (chemo-induced nausea/vomiting) — anticipatory, acute (< 24 h), delayed (24-120 h), breakthrough, refractory. Three-drug regimen for highly emetogenic chemo: 5-HT3 antagonist (palonosetron) + NK1 antagonist (aprepitant/fosaprepitant or netupitant) + dexamethasone. Olanzapine is a 2026 preferred addition for highly emetogenic regimens. Multiday cisplatin requires extended antiemetics.
• Mucositis — basic oral care (soft brush, saline rinses, avoid alcohol-based products), cryotherapy for 5-FU and melphalan mucositis, palifermin for HSCT, magic mouthwash (not evidence-based but commonly tested)
• Fatigue — most common symptom; assess with a 0-10 scale; non-pharmacologic (exercise is first-line — walking 30 min most days), address contributing factors (anemia, depression, sleep, pain, medications); methylphenidate is occasionally used
• Cachexia / anorexia — multimodal: nutritional counseling, small frequent calorie-dense meals, appetite stimulants (megestrol, dronabinol, olanzapine); progestins carry VTE risk
• Neuropathy — platinum and taxane-induced CIPN; duloxetine has the best evidence; dose reduction is the only disease-modifying intervention
• Constipation — opioid-related, vincristine, ondansetron, reduced mobility; aggressive prophylaxis
• Diarrhea — irinotecan (acute vs. late), neratinib, immune checkpoint inhibitor colitis (treat as irAE — steroids, not loperamide, if autoimmune colitis suspected)
• Anxiety and depression — PHQ-9, GAD-7, distress thermometer; SSRIs + CBT; avoid benzodiazepines for chronic use
• Palliative care — early integration improves QOL and survival (Temel trial); distinct from hospice; symptom-focused at any disease stage

Domain V — Oncologic Emergencies (16%)

A major 2026 growth area (up from 12% in 2025 — a 33% relative increase in weight). The 2026 TCO explicitly lists sixteen subtopics, and notably adds "Immune-related adverse events (e.g., cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS))" and sepsis as testable emergencies. Expect at least one vignette per emergency — know the priority action:

Domain VI — Psychosocial Dimensions of Care (10%)

• Cultural, spiritual, religious diversity — culturally congruent care (Leininger), religious restrictions (blood products and Jehovah's Witnesses), spiritual distress assessment
• Financial toxicity — employment, insurance (FMLA, ADA, COBRA, Medicare for disability after 24 months), co-pay assistance programs (Leukemia & Lymphoma Society, CancerCare, HealthWell)
• Altered body image — alopecia, mastectomy, ostomy, head-and-neck surgery; scalp cooling; reach-to-recovery peer programs
• Learning preferences and barriers — literacy, health numeracy, primary language, teach-back method
• Family systems and caregiver burden — family conferences; identify primary caregiver early
• Coping mechanisms — problem-focused vs. emotion-focused; adaptive vs. maladaptive
• Psychosocial distress screening — NCCN Distress Thermometer (0-10); ≥ 4 triggers a referral
• Sexuality, intimacy, fertility — fertility preservation referral before gonadotoxic chemo (sperm banking, oocyte/embryo cryopreservation, GnRH agonists); sexual dysfunction is often under-addressed; PLISSIT model
• Crisis management — suicidal ideation screening; intimate partner violence; elder abuse mandatory reporting

The Immunotherapy Era: Immune-Related Adverse Events (irAEs)

Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab, cemiplimab, dostarlimab) are now first-line in dozens of cancer indications. The OCN writes an increasing number of items on irAE recognition and management — and this is where many ONS courses still under-teach.

The clinical rule: any new symptom in a patient on a checkpoint inhibitor is an irAE until proven otherwise. They can occur during treatment, between cycles, or months after the last dose.

Grade-based management generally follows:

• Grade 1 (mild): continue checkpoint inhibitor, supportive care
• Grade 2 (moderate): hold, consider prednisone 0.5-1 mg/kg/day
• Grade 3-4 (severe / life-threatening): permanently discontinue (most), IV methylprednisolone 1-2 mg/kg/day, add second-line immunosuppressant (infliximab, MMF, IVIG, tocilizumab) if steroid-refractory

Key organ-specific irAEs to recognize:

• Colitis — diarrhea, abdominal pain, blood/mucus; do NOT give loperamide for > grade 1 until colitis is ruled out; infliximab for steroid-refractory (avoid in perforation/sepsis)
• Pneumonitis — new cough, dyspnea, hypoxia; CT chest shows ground-glass opacities; hold + steroids; can be fatal
• Hepatitis — asymptomatic AST/ALT rise → hold; rising bilirubin or grade 3-4 → permanent discontinuation + steroids
• Endocrinopathies — thyroiditis (transient thyrotoxicosis → permanent hypothyroidism, supplement and continue ICI); hypophysitis (headache, fatigue, hyponatremia, low cortisol — often permanent, replace hormones); type 1 diabetes / DKA (new hyperglycemia → insulin, do NOT rely on oral agents); adrenal insufficiency (stress-dose steroids for illness/surgery)
• Myocarditis — rare but among the deadliest; troponin elevation, ECG changes, heart failure; requires permanent discontinuation + high-dose steroids + cardiology
• Dermatitis — rash, pruritus, vitiligo; topical steroids for mild; rule out SJS/TEN for severe
• Nephritis — rising creatinine; hold, steroids, rule out other causes
• Neurologic — Guillain-Barré-like, myasthenia-like, encephalitis; urgent neurology
• Ocular — uveitis, scleritis; ophthalmology + topical/systemic steroids

Combination regimens (ipilimumab + nivolumab) have irAE rates approaching 50-60% for grade 3+ — the OCN will test your ability to triage these patients urgently.

CAR-T and Bispecific Antibodies: CRS and ICANS

CAR-T (chimeric antigen receptor T-cell therapy) is now standard for relapsed/refractory B-cell ALL, large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and multiple myeloma (BCMA-directed). Bispecific T-cell engagers (BsAbs) — teclistamab, talquetamab, elranatamab (MM); mosunetuzumab, epcoritamab, glofitamab (B-NHL); tarlatamab (small cell lung); blinatumomab (B-ALL) — cause the same signature toxicities and are explicitly named in the 2026 OCN TCO. Every OCN candidate in 2026 must know the two defining toxicities and how they apply to both CAR-T and BsAbs.

Cytokine Release Syndrome (CRS)

Onset typically 1-14 days post-infusion (peak around day 2-5 for CAR-T; variable with BsAb step-up dosing, often within 24 hours of each dose escalation). Graded by the ASTCT (American Society for Transplantation and Cellular Therapy) Consensus Criteria (Lee et al. 2019 — the standard replacing older Lee/CARTOX/Penn systems):

Nursing priorities: continuous monitoring (many centers ICU or step-down), q1h vitals during peak window, standing cultures for any fever, rapid escalation. First-line treatment for grade 2+ is tocilizumab (IL-6 receptor antagonist). Corticosteroids are added for higher grades or tocilizumab-refractory disease. Acetaminophen (not NSAIDs — platelet concerns) for fever.

ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome)

Onset days 3-10, often after CRS resolves. Graded using the ICE (Immune Effector Cell-Associated Encephalopathy) score plus level of consciousness, seizures, motor signs, and ICP/cerebral edema:

• ICE score (0-10): orientation (4), naming (3), following commands (1), writing a sentence (1), attention/counting (1)
• Grade 1: ICE 7-9
• Grade 2: ICE 3-6
• Grade 3: ICE 0-2 OR awakens only to voice OR non-convulsive seizures responsive to intervention OR focal edema
• Grade 4: unarousable, prolonged seizures, diffuse cerebral edema, motor deficits

Treatment: corticosteroids (dexamethasone or methylprednisolone); tocilizumab does NOT cross the BBB and is not first-line for isolated ICANS. Seizure prophylaxis (levetiracetam) is often started pre-infusion.

Nursing assessment cadence: ICE score q 8-12 h during the monitoring window; document handwriting daily; patients should not drive for 8 weeks post-infusion (REMS requirement).

USP 800 Hazardous Drug Handling — 2026 Compliance Focus

USP General Chapter <800> became enforceable November 1, 2023, and 2026 surveys from Joint Commission, CMS, and state boards are actively citing non-compliance. Expect OCN items on:

• HD List (NIOSH) — the 2024 NIOSH HD list updates which agents are classified as Group 1 (antineoplastic), Group 2 (non-antineoplastic with HD criteria), Group 3 (reproductive hazard only)
• Assessment of Risk (AoR) documentation for agents not requiring full containment
• Engineering controls — C-PEC (containment primary engineering control — biological safety cabinet Class II B2 or compounding aseptic containment isolator), C-SEC (secondary — negative-pressure buffer room with HEPA, 12 air changes/hour minimum, externally vented)
• PPE — ASTM D6978-tested chemotherapy gloves (double-glove for compounding and administration), ASTM F3267-tested chemotherapy gowns, N95 or PAPR for spills, eye/face protection
• CSTDs (closed-system transfer devices) — required for administration of antineoplastic HDs when dosage form allows; strongly recommended for compounding
• Spill management — spill kit contents, contained area, documentation
• Hazardous waste — yellow chemotherapy container for trace-contaminated (empty vial, tubing); black RCRA container for bulk/P-listed (unused doses of HDs on the EPA P-list like warfarin, epinephrine, mitomycin bulk)
• Surface wipe sampling — recommended every 6 months in HD compounding and administration areas
• Medical surveillance — baseline and periodic health assessments for personnel with HD exposure
• Pregnancy, breastfeeding, and fertility — written alternative duty policies

Pass Rate and Difficulty

Per the 2024 ONCC Examination Statistics, the OCN pass rates were:

• Initial candidates: 65%
• All candidates (including retakes, lapsed, and renewal): 62%

For context, the 2023 OCN statistics showed a 65% initial pass rate and 61% total (2,156 of 3,517 tested passed). These are the most reliably reported figures.

That makes OCN meaningfully harder than CMSRN (73% in 2023) and roughly on par with CPAN/CAPA. The hardest single predictors of failure are under-preparation on Symptom Management and Supportive Care (now 25%) and Treatment Modalities (20%) — together 45% of the 2026 exam. The jump to 16% Oncologic Emergencies (now including CRS/ICANS) means ~23 scored items on emergencies alone. Do not let Psychosocial (now only 10%) steal your study time just because it feels soft-and-easy. The ~36 items in symptom management and ~23 in emergencies are where 2026 exams are won and lost.

The scaled score to pass is 55 on a 25-75 scale. ONCC does not publish the item-level cutoff, but based on modified Angoff methodology, 55 typically corresponds to approximately 70-72% of scored items correct on any given form.

Ready to Start Practice Questions?

Start FREE OCN Practice QuestionsPractice questions with detailed explanations

12-16 Week Study Plan for Working Oncology Nurses

Built for a 36-40 hour bedside or infusion schedule. Two focused study blocks per week (60-75 min each) plus a longer weekend review.

Weeks 1-2: Foundation and Baseline

• Download the 2026 OCN TCO and print it — make sure you are not studying from the older 2025 version
• Take a 50-question diagnostic (use our free OCN practice bank) to identify the weakest two domains
• Skim ONS Core Curriculum for Oncology Nursing, Chapters 1-4 (biology, epidemiology, genetics, clinical trials)

Weeks 3-4: Oncology Nursing Practice (Domain II)

• Carcinogenesis, immunology, TNM staging, histologic grade
• Lab interpretation drill: CBC/diff, ANC calculation, electrolyte abnormalities, tumor markers
• Complete 30 practice questions in this domain; review every rationale

Weeks 5-7: Treatment Modalities (Domain III)

• Build a chemotherapy class table (alkylating, antimetabolite, anthracycline, vinca, taxane, platinum, topoisomerase) — memorize MOA, key toxicity, nursing pearl
• Immunotherapy deep dive: checkpoint inhibitor list and targets; CAR-T products and constructs
• Radiation: external beam vs. brachytherapy (LDR/HDR/seed) vs. systemic radiopharmaceuticals; radiation safety (time, distance, shielding)
• HSCT: autologous vs. allogeneic; acute vs. chronic GVHD; VOD
• VAD types and vesicant administration rules
• 50 practice questions + rationales

Weeks 8-10: Symptom Management and Supportive Care (Domain IV — 25%, biggest domain)

• Pain: WHO ladder, opioid equivalents, breakthrough dosing, adjuvants, OIC prophylaxis
• CINV: acute/delayed/anticipatory; three-drug standard for HEC
• Mucositis, fatigue, cachexia, neuropathy
• Palliative care principles (Temel study); hospice eligibility; end-of-life symptom package
• 60 practice questions

Week 11: Oncologic Emergencies (Domain V — 16%, expanded in 2026)

• Build a one-page emergency table (you can laminate the one above). Drill the priority action for all 16 ONCC-listed emergencies including CRS, ICANS, and sepsis (new in 2026).
• 40-item timed emergency-only quiz (this domain now = ~23 scored items on test day)

Week 12: Care Continuum + Psychosocial (Domains I and VI)

• Screening guidelines (USPSTF)
• Hereditary syndromes (BRCA, Lynch, Li-Fraumeni, FAP)
• Survivorship and end-of-life
• NCCN Distress Thermometer; PLISSIT; financial toxicity resources
• 30 practice questions

Weeks 13-14: irAE and CAR-T Intensive

• Organ-specific irAE algorithm
• CRS/ICANS grading (ASTCT, ICE score)
• Tocilizumab vs. steroid decision tree
• 40 focused practice items

Week 15: First Full-Length Simulation

• 165 questions, 3 hours, no interruptions, one bathroom break max
• Score by domain; identify any < 65% and rebuild that section

Week 16: Second Full-Length + Confidence Taper

• Second 165-question simulation (different bank)
• Two days before exam: rest, hydrate, sleep
• Exam day: protein + complex carb breakfast, arrive 30 min early, bring two IDs

Total practice volume target: 600-800 items with reviewed rationales. That is the single best predictor of passing.

Recommended Resources

• Core Curriculum for Oncology Nursing, 6th edition (ONS). The authoritative source and primary ONCC reference.
• Study Guide for the Core Curriculum for Oncology Nursing, 6th edition. Matches chapters to the Core Curriculum — use it for targeted review.
• ONS/ONCC Chemotherapy Immunotherapy Certificate course. Not required for OCN, but the content maps tightly to Domain III and it satisfies the chemo-immunotherapy competency most infusion centers already require.
• Oncology Nursing Review, 7th ed. (Yarbro et al.) — the more clinical counterpart to the Core Curriculum, with richer vignettes.
• ONS Practice Questions (ONS member store).
• Our FREE OCN practice bank — blueprint-mapped, rationale-driven, with live updates when the TCO changes.

Test-Taking Strategies

• ABCs on every emergency item. Airway, Breathing, Circulation always precede everything else — even "notify the provider." The only answer that beats ABC is a safety-based item that identifies an immediate life-threat (e.g., stopping an extravasation before it progresses).
• Maslow hierarchy tiebreakers. When two answers are both "safe," pick the one that addresses the most immediate physiologic need.
• Prioritize worst-first in scenarios with multiple patients. The OCN loves "which patient should the charge nurse see first" items. The answer is always the most unstable physiology (new hypotension, new hypoxia, new neuro change) — even if another patient sounds emotionally urgent.
• Oncologic-emergency trigger words. "New back pain with weakness" → cord compression. "Facial swelling + JVD" → SVC. "High WBC after first chemo with Burkitt" → TLS. "Fever with ANC 400" → febrile neutropenia.
• Checkpoint inhibitor trap. If a patient on pembro/nivo/ipi/atezo/durva develops any new symptom — think irAE first, not "common flu" or "food poisoning."
• Eliminate before you pick. Cross off two options that are clearly wrong. Then compare the two remaining side by side — the OCN rarely leaves two "correct" answers, but it leaves two plausible ones.
• Do not over-read the vignette. If the stem doesn't mention a finding, don't assume it.

Cost, Retake, and Recertification

Exam cost (2026)

• ONS/APHON member: $300 (age 65+: $225)
• Non-member: $420 (age 65+: $315)
• Double Take option (pay $100 upfront for one retest if you fail): a good buy if you are uncertain — retest fee alone is normally the full exam cost.

Retake policy

If you do not pass, you must wait 90 days before retesting and may take the OCN up to four times in a 12-month period. A new application is required for each attempt.

Recertification — every 4 years

Three options:

1. Points (most common). Take the ILNA (Individual Learning Needs Assessment) to receive a subject-area point plan, then earn points via nursing CE, CMEs, academic coursework, presentations, publications, or precepting. Fee: ONS/APHON member $240 early-bird / $340 final; non-member $360 early-bird / $460 final.
2. Test — retake the OCN. Fee: ONS/APHON member $300; non-member $420. Good option if you feel your knowledge base is current and you do not want to track points.
3. Test + Points combination — member $400 early-bird / $500 final; non-member $520 early-bird / $620 final.

Renewal deadlines are September 15 (early-bird, save $100) and October 15 (final) of the year your certification expires. Testing-option candidates must apply by September 1 to secure the 90-day window.

Salary and Career Impact

Per the U.S. Bureau of Labor Statistics (OOH May 2024), the median RN salary is $93,600. Oncology nurses typically earn at or slightly above the median RN wage, with a meaningful certification premium.

• Inpatient oncology / BMT staff RN: $85,000-$120,000 (varies by MSA and shift differential)
• Ambulatory infusion RN: $80,000-$110,000, with daytime schedule (a major lifestyle advantage)
• Clinical trials RN / research coordinator: $85,000-$130,000
• Nurse navigator / survivorship coordinator: $85,000-$115,000
• Oncology nurse manager: $105,000-$150,000+

OCN-certified RNs typically earn a 3-8% premium over non-certified oncology RNs at the same experience level, and many employers offer certification bonuses ($500-$2,500) on initial pass plus an annual differential. Magnet hospitals use certification percentages in Magnet recertification — so being certified genuinely helps your unit.

Career pathway after OCN

• Subspecialty ONCC credentials: BMTCN (blood and marrow transplant), CBCN (breast care)
• Advanced practice: AOCNP (NP, post-MSN/DNP) or AOCNS (CNS)
• Leadership: oncology nurse manager, clinical educator, QOPI quality coordinator
• Research: oncology clinical research coordinator, investigator-initiated trial nurse
• Informatics / industry: pharmaceutical or device oncology clinical science liaison

Common Mistakes

1. Confusing TLS priority. Many candidates pick "administer rasburicase" as the first action. The first action on a bulky-lymphoma patient about to start chemo is aggressive IV hydration. Rasburicase is the rescue in established TLS — and is contraindicated in G6PD deficiency.
2. Missing checkpoint-inhibitor diarrhea as colitis. Loperamide is appropriate for most chemo diarrhea, but not for suspected immune-mediated colitis — give high-dose steroids, not anti-motility.
3. Ignoring cord compression as a time emergency. Steroids + MRI + radiation or surgery must happen in hours, not days. A patient who is still ambulating at presentation has the best chance of staying ambulatory if treated emergently.
4. Under-prioritizing neutropenic fever. The single highest-yield rule: blood cultures drawn and broad-spectrum antibiotics in the vein within 1 hour. Do not wait for CBC, chest X-ray, or medicine consult.
5. Confusing mesna with leucovorin. Mesna prevents hemorrhagic cystitis with cyclophosphamide/ifosfamide. Leucovorin rescues from methotrexate. They are not interchangeable.
6. Placing vincristine on an IV bag of anything. Vincristine must be dispensed in a mini-bag (per ISMP/NCCN safe-handling standards) to prevent accidental intrathecal administration — which is uniformly fatal.
7. Administering radiation safety incorrectly. Permanent seed brachytherapy (e.g., prostate) requires different visitor precautions than HDR temporary sources or systemic radiopharmaceuticals.
8. Assuming trastuzumab cardiotoxicity = doxorubicin cardiotoxicity. Trastuzumab is typically reversible with drug discontinuation and HF therapy; doxorubicin cardiotoxicity is dose-dependent and often permanent.
9. Applying cold to vinca extravasation. Cold is appropriate for most vesicants; vinca alkaloids need warm compresses + hyaluronidase.
10. Missing hypophysitis. Fatigue + headache + hyponatremia + low cortisol + low TSH in a patient on ipilimumab = hypophysitis, not "just tired."

OCN vs. CBCN vs. BMTCN vs. AOCNP vs. CPON/CPHON — The ONCC Credential Ladder

The typical pathway: OCN → specialty credential (BMTCN or CBCN) → AOCNP/AOCNS if you complete graduate school. Pediatric-focused nurses pursue CPHON/CPON instead of OCN.

Final Call to Action

If you have the hours and the CE, there is no reason to wait. The 2026 OCN blueprint is stable, the fees are frozen, and every month you delay is a month you are testing your own certification-bonus clock.

Start FREE OCN Practice QuestionsPractice questions with detailed explanations

Official Sources (2026)

• ONCC Oncology Certified Nurse (OCN) page — current fees, eligibility, scheduling
• 2026 OCN Test Content Outline (PDF) — official blueprint, effective 2026 (published November 2025)
• 2026 OCN Test References — ONCC-approved primary references
• 2024 Examination Statistics and Pass Rates (PDF) — most recent published pass-rate data
• ONCC Test Scores and Passing Score — scaled score methodology
• ONCC OCN Recertification — four-year renewal options
• ONCC Renewal Deadlines and Fees — 2026 renewal pricing
• USP General Chapter <800> Hazardous Drugs — enforceable safe-handling standard
• NIOSH Hazardous Drug List 2024 — HD classification
• U.S. BLS Registered Nurses (OOH) — median RN wage $93,600 (May 2024)